Commentary
Volume 10:02, 2025

Journal of Oncology Medicine & Practice

ISSN: 2576-3857

Open Access

Epigenetic Regulation of PD-L1 in NSCLC Therapy

Amina El-Sayed*

Department of Radiation Oncology, Cairo University, Cairo 12613, Egypt

Introduction

The expression of Programmed Death-Ligand 1 (PD-L1) has emerged as a critical determinant of the tumor immune microenvironment in Non-Small Cell Lung Cancer (NSCLC), significantly impacting the efficacy of immune checkpoint inhibitors (ICIs) [1]. This molecule plays a pivotal role in immune evasion by engaging with the PD-1 receptor on T cells, thereby suppressing anti-tumor immune responses. Understanding the intricate regulatory mechanisms that control PD-L1 expression is therefore paramount for developing more effective therapeutic strategies in NSCLC [1].

Epigenetic modifications, which alter gene expression without changing the underlying DNA sequence, are increasingly recognized as central players in the modulation of PD-L1 [1]. These modifications encompass a range of processes, including DNA methylation and histone modifications, which collectively orchestrate the transcriptional landscape of cancer cells [1]. Recent research has illuminated the profound influence of these epigenetic changes on PD-L1 upregulation in NSCLC, contributing to immune suppression and resistance to therapy [1].

One significant avenue of epigenetic regulation involves DNA methylation, particularly within the promoter regions of genes [1]. Aberrant methylation patterns in NSCLC have been linked to altered PD-L1 expression, often leading to increased levels that promote immune evasion [1]. This dysregulation is particularly relevant in the context of resistance to ICIs, suggesting that epigenetic profiling could offer predictive value for treatment outcomes [1].

Histone modifications represent another crucial layer of epigenetic control over PD-L1 expression [1]. These modifications, such as acetylation and trimethylation, can dynamically alter chromatin structure, thereby influencing the accessibility of transcription factors to gene promoters [1]. Research has demonstrated that specific histone modifications are associated with either the activation or repression of PD-L1 transcription in NSCLC cells [1].

Histone deacetylase (HDAC) inhibitors, for instance, have shown promise in modulating PD-L1 expression [2]. By affecting histone acetylation, these inhibitors can lead to the downregulation of PD-L1, potentially restoring T-cell mediated anti-tumor immunity [2]. The combination of HDAC inhibitors with ICIs is being explored as a synergistic approach for treating NSCLC [2].

Beyond DNA and histone modifications, non-coding RNAs, including microRNAs (miRNAs), also exert significant epigenetic control over PD-L1 expression [3]. These small RNA molecules can target PD-L1 mRNA directly or influence upstream signaling pathways involved in its regulation [3]. The potential of miRNA-based therapies to modulate PD-L1 levels and enhance immunotherapy responses is a burgeoning area of investigation [3].

Enhancer RNAs (eRNAs) have also been identified as novel regulators of PD-L1 transcription, contributing to the epigenetic landscape of this immune checkpoint ligand [5]. These eRNAs can interact with transcription factors and chromatin modifiers to promote PD-L1 expression, offering new targets for therapeutic intervention [5].

Polycomb Repressive Complex 2 (PRC2), and its core component enhancer of zeste homolog 2 (EZH2), play a role in epigenetic regulation through histone methylation [8, 10]. PRC2-mediated H3K27 trimethylation can suppress PD-L1 expression, while inhibition of PRC2 or EZH2 leads to increased PD-L1 and enhanced anti-tumor immunity [8, 10]. This highlights PRC2 and EZH2 as potential therapeutic targets for overcoming immunotherapy resistance [8, 10].

The epigenetic reprogramming of the tumor immune microenvironment in NSCLC, with a specific focus on PD-L1, is a complex process [9]. Changes in DNA methylation and histone modifications contribute to a pro-tumorigenic and immunosuppressive environment, underscoring the importance of understanding these alterations for developing effective immunotherapeutic strategies [9].

In summary, the interplay between various epigenetic mechanisms and PD-L1 expression in NSCLC is multifaceted and profoundly influences the tumor's interaction with the immune system [6]. Targeting these epigenetic pathways holds significant therapeutic promise for enhancing anti-tumor immunity and overcoming resistance to current treatments [6].

Description

The expression of Programmed Death-Ligand 1 (PD-L1) is a critical factor influencing the efficacy of immunotherapies in Non-Small Cell Lung Cancer (NSCLC), and its regulation is intricately linked to epigenetic mechanisms [1]. Epigenetic modifications, encompassing DNA methylation, histone modifications, and non-coding RNAs, profoundly impact PD-L1 expression, thereby dictating the tumor's ability to evade immune surveillance [1].

DNA methylation, a key epigenetic alteration, plays a significant role in modulating PD-L1 expression in NSCLC [1, 4]. Aberrant methylation patterns within the PD-L1 promoter can lead to increased PD-L1 levels, contributing to immune suppression and resistance to immune checkpoint inhibitors (ICIs) [4, 7]. Specifically, methylation of CpG islands in the PD-L1 promoter has been associated with elevated PD-L1 expression and poor treatment outcomes in patients receiving anti-PD-1 therapy [4, 7].

Histone modifications represent another crucial layer of epigenetic control over PD-L1 expression [1, 8]. These modifications dynamically alter chromatin structure, influencing the accessibility of transcriptional machinery to the PD-L1 gene [1, 8]. For instance, Polycomb Repressive Complex 2 (PRC2)-mediated histone methylation, such as H3K27 trimethylation, has been shown to suppress PD-L1

expression [8].

Histone deacetylase (HDAC) inhibitors have emerged as a strategy to modulate PD-L1 expression by affecting histone acetylation [2]. Inhibition of HDACs can lead to the downregulation of PD-L1, thereby restoring T-cell mediated anti-tumor immunity [2]. This suggests that combining HDAC inhibitors with ICIs could be a promising therapeutic approach for NSCLC [2].

MicroRNAs (miRNAs) are also involved in the epigenetic regulation of PD-L1 expression in NSCLC [3]. These small non-coding RNAs can directly target PD-L1 mRNA or modulate upstream signaling pathways that control its expression [3]. The identification of specific miRNAs that regulate PD-L1 offers potential for miRNA-based therapeutic interventions to enhance immunotherapy responses [3].

Enhancer RNAs (eRNAs) represent a novel class of epigenetic regulators that influence PD-L1 transcription in NSCLC [5]. These eRNAs can interact with transcription factors and chromatin modifiers to promote PD-L1 expression, opening new avenues for therapeutic targeting to modulate anti-tumor immunity [5].

The enhancer of zeste homolog 2 (EZH2), a key component of PRC2, has been implicated in the epigenetic regulation of PD-L1 in NSCLC [10]. Inhibition of EZH2 has been shown to reduce PD-L1 expression, thereby sensitizing NSCLC cells to T-cell mediated killing and improving responses to anti-PD-1 therapy [10].

The epigenetic reprogramming of the tumor immune microenvironment in NSCLC, with a particular focus on PD-L1, contributes to a pro-tumorigenic and immunosuppressive milieu [9]. Understanding these epigenetic alterations is vital for developing effective immunotherapeutic strategies that overcome immune evasion [9].

Collectively, these epigenetic mechanisms—DNA methylation, histone modifications, miRNAs, and eRNAs—offer a complex network that regulates PD-L1 expression in NSCLC [6]. The dysregulation of these pathways contributes to immune suppression and therapeutic resistance, highlighting the importance of targeting them for improved clinical outcomes [6].

In conclusion, the comprehensive understanding of epigenetic regulation of PD-L1 in NSCLC provides a foundation for developing novel therapeutic strategies aimed at enhancing anti-tumor immunity and overcoming resistance to existing treatments [6].

Conclusion

This collection of research explores the multifaceted epigenetic regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Epigenetic mechanisms, including DNA methylation, histone modifications (such as those regulated by HDACs, PRC2, and EZH2), microRNAs, and enhancer RNAs, are shown to significantly influence PD-L1 expression. Aberrant epigenetic changes often lead to increased PD-L1 levels, promoting immune evasion and contributing to resistance against immunotherapy. The findings highlight the potential of targeting these epigenetic pathways, using agents like HDAC inhibitors or EZH2 inhibitors, either alone or in combination with immune checkpoint inhibitors, to restore anti-tumor immunity and improve treatment outcomes in NSCLC patients. Furthermore, the epigenetic landscape of the tumor immune microenvironment and the role of PD-L1 in this context are crucial for developing effective therapeutic strategies.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Jing Wang, Chenxi Yu, Xudong Li. "Epigenetic Regulation of PD-L1 in Cancer: Mechanisms and Therapeutic Implications." *Cancer Immunol Immunother* 70 (2021):1478-1487.
2. Ying Sun, Jian Li, Wei Zhang. "HDAC inhibitors as a strategy to overcome immune evasion in non-small cell lung cancer." *Clin Epigenetics* 14 (2022):115.
3. Bingbing Wang, Yanping Zhang, Junping Li. "MicroRNA-mediated regulation of PD-L1 expression in non-small cell lung cancer." *Front Oncol* 10 (2020):1846.
4. Xiaojiao Wang, Huijuan Li, Mingxing Xie. "DNA methylation of PD-L1 promoter in non-small cell lung cancer and its correlation with immunotherapy." *J Thorac Dis* 11 (2019):5607-5615.
5. Xianjuan Li, Hongyan Guo, Leping Chen. "Epigenetic regulation of PD-L1 by enhancer RNAs in non-small cell lung cancer." *Cell Death Differ* 30 (2023):853-867.
6. Shuai Li, Fang Zhao, Yan Zhang. "Epigenetic Mechanisms Driving PD-L1 Expression in Non-Small Cell Lung Cancer and Therapeutic Opportunities." *Semin Cancer Biol* 75 (2022):86-99.
7. Yixuan Wang, Lei Zhao, Min Li. "Aberrant DNA Methylation of PD-L1 Promoter is Associated with Poor Response to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer." *Cancer Res* 80 (2020):3456-3465.
8. Chao Wang, Jian Li, Bin Yang. "PRC2-mediated H3K27 trimethylation regulates PD-L1 expression in non-small cell lung cancer." *Oncogene* 40 (2021):4210-4220.
9. Dongmei Li, Fei Wang, Wei Chen. "Epigenetic Reprogramming of the Tumor Immune Microenvironment in Non-Small Cell Lung Cancer." *Cancer Cell* 41 (2023):677-692.
10. Xiaojiao Wang, Guanghui Wang, Yong Li. "EZH2 Inhibition Sensitizes Non-Small Cell Lung Cancer to Anti-PD-1 Therapy by Downregulating PD-L1." *Nat Commun* 11 (2020):4092.

How to cite this article: El-Sayed, Amina. "Epigenetic Regulation of PD-L1 in NSCLC Therapy." *J Oncol Med & Pract* 10 (2025):296.

Address for Correspondence: Amina, El-Sayed, Department of Radiation Oncology, Cairo University, Cairo 12613, Egypt, E-mail: amina.elsayed@cu.edu.eg

Received: 01-Apr-2025, Manuscript No. jomp-26-185077; **Editor assigned:** 03-Apr-2025, PreQC No. P-185077; **Reviewed:** 17-Apr-2025, QC No. Q-185077; **Revised:** 22-Apr-2025, Manuscript No. R-185077; **Published:** 29-Apr-2025, DOI: 10.37421/2576-3857.2025.10.296